# Exyn Technologies, Inc.: financial statements, quarterly

EXYN · Nasdaq · CIK 1960355 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/exyn.md) · [Financials](/companies/exyn/financials.md) · [Filings](/companies/exyn/filings.md) · [Insiders](/companies/exyn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/exyn/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,218](/filings/0001104659-26-080820.md) | [1,358](/filings/0001104659-26-098902.md) | [1,191](/filings/0001104659-26-080820.md) | [950](/filings/0001104659-26-098902.md) |
| Cost of revenue | $k | [785](/filings/0001104659-26-080820.md) | [806](/filings/0001104659-26-098902.md) | [688](/filings/0001104659-26-080820.md) | [504](/filings/0001104659-26-098902.md) |
| Gross profit | $k | [433](/filings/0001104659-26-080820.md) | [552](/filings/0001104659-26-098902.md) | [502](/filings/0001104659-26-080820.md) | [445](/filings/0001104659-26-098902.md) |
| Research and development | $k | [1,334](/filings/0001104659-26-080820.md) | [1,187](/filings/0001104659-26-098902.md) | [1,215](/filings/0001104659-26-080820.md) | [1,359](/filings/0001104659-26-098902.md) |
| Selling, general and administrative | $k | [1,411](/filings/0001104659-26-080820.md) | [1,319](/filings/0001104659-26-098902.md) | [1,960](/filings/0001104659-26-080820.md) | [3,016](/filings/0001104659-26-098902.md) |
| Operating income | $k | [(2,513)](/filings/0001104659-26-080820.md) | [(2,156)](/filings/0001104659-26-098902.md) | [(2,873)](/filings/0001104659-26-080820.md) | [(4,127)](/filings/0001104659-26-098902.md) |
| Interest expense | $k | [81.3](/filings/0001104659-26-080820.md) | [87.8](/filings/0001104659-26-098902.md) | [336](/filings/0001104659-26-080820.md) | [446](/filings/0001104659-26-098902.md) |
| Net income | $k | [(2,580)](/filings/0001104659-26-098902.md) | [(2,922)](/filings/0001104659-26-098902.md) | [(3,239)](/filings/0001104659-26-098902.md) | [(6,894)](/filings/0001104659-26-098902.md) |
| Diluted EPS | $ per share | [(1.96)](/filings/0001104659-26-080820.md) | [(2.22)](/filings/0001104659-26-098902.md) | [(2.45)](/filings/0001104659-26-080820.md) | [(1.55)](/filings/0001104659-26-098902.md) |
| Basic EPS | $ per share | [(1.96)](/filings/0001104659-26-080820.md) | [(2.22)](/filings/0001104659-26-098902.md) | [(2.45)](/filings/0001104659-26-080820.md) | [(1.55)](/filings/0001104659-26-098902.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | period not labelled (2026-08-19) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [0.8](/filings/0001104659-26-098902.md) | [1.1](/filings/0001104659-26-080820.md) | [7.8](/filings/0001104659-26-098902.md) | [4.5](/filings/0001104659-26-098902.md) |
| Current assets | $m | not reported | not reported | not reported | [5.1](/filings/0001104659-26-098902.md) | [4.5](/filings/0001104659-26-080820.md) | [11.2](/filings/0001104659-26-098902.md) | not reported |
| Total assets | $m | not reported | not reported | not reported | [5.9](/filings/0001104659-26-098902.md) | [5.2](/filings/0001104659-26-080820.md) | [11.8](/filings/0001104659-26-098902.md) | not reported |
| Current liabilities | $m | not reported | not reported | not reported | [17.0](/filings/0001104659-26-098902.md) | [18.6](/filings/0001104659-26-080820.md) | [6.1](/filings/0001104659-26-098902.md) | not reported |
| Total liabilities | $m | not reported | not reported | not reported | [17.2](/filings/0001104659-26-098902.md) | [19.5](/filings/0001104659-26-080820.md) | [6.2](/filings/0001104659-26-098902.md) | not reported |
| Long-term debt | $m | not reported | not reported | not reported | [6.1](/filings/0001104659-26-098902.md) | [8.1](/filings/0001104659-26-080820.md) | [1.7](/filings/0001104659-26-098902.md) | not reported |
| Shareholders' equity | $m | [0.1](/filings/0001104659-26-098902.md) | [(2.3)](/filings/0001104659-26-098902.md) | [(5.0)](/filings/0001104659-26-098902.md) | [(11.3)](/filings/0001104659-26-098902.md) | [(14.3)](/filings/0001104659-26-098902.md) | [5.6](/filings/0001104659-26-098902.md) | not reported |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,511)](/filings/0001104659-26-080820.md) | [(2,196) d](/filings/0001104659-26-098902.md) | [(1,627)](/filings/0001104659-26-080820.md) | [(5,449) d](/filings/0001104659-26-098902.md) |
| Capital expenditure | $k | [11.4](/filings/0001104659-26-080820.md) | [2.3 d](/filings/0001104659-26-098902.md) | [3.6](/filings/0001104659-26-080820.md) | [25.1 d](/filings/0001104659-26-098902.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [1,317](/filings/0001104659-26-080820.md) | [1,317](/filings/0001104659-26-098902.md) | [1,323](/filings/0001104659-26-080820.md) | [4,454](/filings/0001104659-26-098902.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,953,957 at 2026-08-05, from the cover of the [10-Q/A filed 2026-08-20](/filings/0001104659-26-098902.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.